PubRank

Robert C Seeger

Author PubWeight™ 72.50‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. J Clin Oncol 2009 5.12
2 Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med 2005 4.92
3 The genetic landscape of high-risk neuroblastoma. Nat Genet 2013 4.71
4 Chromosome 6p22 locus associated with clinically aggressive neuroblastoma. N Engl J Med 2008 3.80
5 ZNF423 is critically required for retinoic acid-induced differentiation and is a marker of neuroblastoma outcome. Cancer Cell 2009 2.93
6 Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification. J Natl Cancer Inst 2006 2.79
7 Sparse representation and Bayesian detection of genome copy number alterations from microarray data. Bioinformatics 2008 2.65
8 Common variations in BARD1 influence susceptibility to high-risk neuroblastoma. Nat Genet 2009 2.47
9 Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. Lancet Oncol 2013 2.25
10 Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children's Oncology Group study. J Clin Oncol 2010 2.00
11 A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group. Clin Cancer Res 2006 1.91
12 ATM is down-regulated by N-Myc-regulated microRNA-421. Proc Natl Acad Sci U S A 2010 1.85
13 Molecular characterization of the pediatric preclinical testing panel. Clin Cancer Res 2008 1.84
14 NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome. Cell 2010 1.81
15 Valpha24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages. J Clin Invest 2009 1.78
16 Interleukin-6 in the bone marrow microenvironment promotes the growth and survival of neuroblastoma cells. Cancer Res 2009 1.77
17 Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study. J Clin Oncol 2005 1.60
18 Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study. J Clin Oncol 2010 1.57
19 Genotypes of NK cell KIR receptors, their ligands, and Fcγ receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy. Cancer Res 2010 1.51
20 Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. N Engl J Med 2010 1.47
21 Natural killer T cells infiltrate neuroblastomas expressing the chemokine CCL2. J Exp Med 2004 1.43
22 Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma. J Clin Oncol 2012 1.37
23 Impact of radiotherapy for high-risk neuroblastoma: a Children's Cancer Group study. Int J Radiat Oncol Biol Phys 2003 1.30
24 The MYCN enigma: significance of MYCN expression in neuroblastoma. Cancer Res 2006 1.28
25 Oncogene MYCN regulates localization of NKT cells to the site of disease in neuroblastoma. J Clin Invest 2007 1.28
26 Critical role of STAT3 in IL-6-mediated drug resistance in human neuroblastoma. Cancer Res 2013 1.26
27 Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study. J Clin Oncol 2006 1.25
28 An integrated cross-platform prognosis study on neuroblastoma patients. Genomics 2008 1.10
29 Common variation at BARD1 results in the expression of an oncogenic isoform that influences neuroblastoma susceptibility and oncogenicity. Cancer Res 2012 1.09
30 Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: a report from the CCG and COG. Pediatr Blood Cancer 2009 1.00
31 Growth and activation of natural killer cells ex vivo from children with neuroblastoma for adoptive cell therapy. Clin Cancer Res 2013 1.00
32 Antidisialoganglioside/granulocyte macrophage-colony-stimulating factor fusion protein facilitates neutrophil antibody-dependent cellular cytotoxicity and depends on FcgammaRII (CD32) and Mac-1 (CD11b/CD18) for enhanced effector cell adhesion and azurophil granule exocytosis. Blood 2002 0.98
33 Novel cancer vaccine based on genes of Salmonella pathogenicity island 2. Int J Cancer 2010 0.97
34 Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: a report from the Children's Oncology Group. Cancer 2013 0.96
35 Outcome of high-risk stage 3 neuroblastoma with myeloablative therapy and 13-cis-retinoic acid: a report from the Children's Oncology Group. Pediatr Blood Cancer 2009 0.94
36 Peripheral neuroblastic tumors with genotype-phenotype discordance: a report from the Children's Oncology Group and the International Neuroblastoma Pathology Committee. Pediatr Blood Cancer 2012 0.91
37 GABAergic system gene expression predicts clinical outcome in patients with neuroblastoma. J Clin Oncol 2004 0.89
38 Lenalidomide overcomes suppression of human natural killer cell anti-tumor functions by neuroblastoma microenvironment-associated IL-6 and TGFβ1. Cancer Immunol Immunother 2013 0.89
39 De novo identification of MIZ-1 (ZBTB17) encoding a MYC-interacting zinc-finger protein as a new favorable neuroblastoma gene. Clin Cancer Res 2007 0.88
40 Membrane-bound TRAIL supplements natural killer cell cytotoxicity against neuroblastoma cells. J Immunother 2013 0.86
41 TrkA expression in peripheral neuroblastic tumors: prognostic significance and biological relevance. Cancer 2004 0.86
42 Age-dependent prognostic effect by Mitosis-Karyorrhexis Index in neuroblastoma: a report from the Children's Oncology Group. Pediatr Dev Pathol 2014 0.86
43 Enlarged and prominent nucleoli may be indicative of MYCN amplification: a study of neuroblastoma (Schwannian stroma-poor), undifferentiated/poorly differentiated subtype with high mitosis-karyorrhexis index. Cancer 2005 0.85
44 Cdc6 knockdown inhibits human neuroblastoma cell proliferation. Mol Cell Biochem 2008 0.76